drugset / Trial / NCT01830478

Lenalidomide Plus Rituximab (R) in Non Follicular NHL

NCT01830478 ↗

Phase 2 Unknown 44 enrolled Gruppo Italiano Studio Linfomi
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether lenalidomide in association with rituximab is effective in the treatment of patients with indolent non follicular NHL relapsed after \>=2, but less than 4 prior lines of (immuno)chemotherapy.

Timeline

Start
2009-04
Primary completion
2010-12
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 20 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications